Cargando…

Olaparib-induced pseudoporphyria in a patient with ovarian cancer

Detalles Bibliográficos
Autores principales:	Clark, Abigale, Weissman, Amanda S., Crowson, Arthur Neil, Hirshburg, Jason
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10424066/ https://www.ncbi.nlm.nih.gov/pubmed/37583835 http://dx.doi.org/10.1016/j.jdcr.2023.07.011

Ejemplares similares

Pseudoporphyria induced by hemodialysis
por: Bergler-Czop, Beata, et al.
Publicado: (2014)

Drug induced pseudoporphyria in CKD: A case report
por: Quaiser, S., et al.
Publicado: (2015)

Furosemide-induced pseudoporphyria in a patient with chronic kidney disease: case report
por: Pavanelli, Giovana Memari, et al.
Publicado: (2018)

Pseudoporphyria in a haemodialysis patient
por: Lee, Cheng-Chia, et al.
Publicado: (2010)

Pseudoporphyria: A Case Report
por: Garg, Taru, et al.
Publicado: (2015)

Pseudoporphyria Associated with Nonhemodialyzed Renal Insufficiency, Successfully Treated with Oral N-Acetylcysteine
por: Katoulis, A. C., et al.
Publicado: (2013)

Pneumocystis Pneumonia in a Patient with Ovarian Cancer Receiving Olaparib Therapy
por: Himeji, Daisuke, et al.
Publicado: (2021)

Olaparib treatment for BRCA-mutant ovarian cancer with leptomeningeal disease
por: Bangham, Madeleine, et al.
Publicado: (2016)

D-2-Hydroxyglutaric Aciduria with Enchondromatosis and Angiokeratoma Circumscriptum
por: Preston, Allie, et al.
Publicado: (2019)

Olaparib in the management of ovarian cancer
por: Bixel, Kristin, et al.
Publicado: (2015)

Olaparib in Epithelial Ovarian Cancer
por: Anastasia, Paula J.
Publicado: (2016)

Pseudoporphyria Induced by Voriconazole in a 10-year-old Boy: A Case Report and Review of the Literature
por: CAROPPO, Francesca, et al.
Publicado: (2023)

Early onset pauciarticular arthritis is the major risk factor for naproxen-induced pseudoporphyria in juvenile idiopathic arthritis
por: Schäd, Susanne G, et al.
Publicado: (2007)

Long-term response to olaparib in a patient with metastatic pancreatic cancer associated with hereditary breast and ovarian cancer syndrome
por: Tsuneizumi, Michiko, et al.
Publicado: (2022)

Olaparib-Induced Immune-Mediated Liver Injury
por: Alshelleh, Mohammad, et al.
Publicado: (2022)

Olaparib-Induced Purpuric Drug Eruption in a Patient with Castration-Resistant Prostate Cancer
por: Sekine, Mana, et al.
Publicado: (2023)

Profile of olaparib in the treatment of advanced ovarian cancer
por: Chase, Dana M, et al.
Publicado: (2016)

Efficiency of olaparib in colorectal cancer patients with an alteration of the homologous repair protein
por: Ghiringhelli, Francois, et al.
Publicado: (2016)

Olaparib in an ovarian cancer patient with end-stage renal disease and hemodialysis
por: Baum, Joanna, et al.
Publicado: (2023)

Olaparib as maintenance treatment for patients with platinum-sensitive relapsed ovarian cancer
por: Ledermann, Jonathan A., et al.
Publicado: (2019)

Olaparib for metastatic breast cancer in a patient with a germline PALB2 variant
por: Kuemmel, Sherko, et al.
Publicado: (2020)

Randomised phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer (OCTOVA): a study protocol
por: Mansouri, Anita, et al.
Publicado: (2021)

Olaparib Treatment in a Patient with Advanced Gallbladder Cancer Harboring BRCA1 Mutation
por: Li, Xiaofen, et al.
Publicado: (2021)

Olaparib and advanced ovarian cancer: Summary of the past and looking into the future
por: Maiorano, Brigida Anna, et al.
Publicado: (2023)

Role of Olaparib as Maintenance Treatment for Ovarian Cancer: The Evidence to Date
por: Montemorano, Lauren, et al.
Publicado: (2019)

Olaparib is effective for recurrent urothelial carcinoma with BRCA2 pathogenic germline mutation: first report on olaparib response in recurrent UC
por: Yang, Hong, et al.
Publicado: (2020)

BRCA2 reversion mutation confers resistance to olaparib in breast cancer
por: Yamamoto, Shinya, et al.
Publicado: (2023)

A Novel Adverse Event Associated with Olaparib Therapy in a Patient with Metastatic Breast Cancer
por: Wheelden, Megan, et al.
Publicado: (2018)

Response to Olaparib in a Patient with Germline BRCA2 Mutation and Breast Cancer Leptomeningeal Carcinomatosis
por: Exman, Pedro, et al.
Publicado: (2019)

Response of BRCA1-mutated gallbladder cancer to olaparib: A case report
por: Xie, Yuan, et al.
Publicado: (2016)

Olaparib Monotherapy for BRIP1-Mutated High-Grade Serous Endometrial Cancer
por: Nakamura, Kohei, et al.
Publicado: (2020)

Recurrent Cervical Cancer Treated Successfully with Single-Agent PARP-Inhibitor, Olaparib
por: Gross, Maya, et al.
Publicado: (2022)

Emerging treatment options for recurrent ovarian cancer: the potential role of olaparib
por: Shaw, Heather M, et al.
Publicado: (2013)

Systematic Review of Olaparib in the Treatment of Recurrent Platinum Sensitive Ovarian Cancer
por: Chen, Qian, et al.
Publicado: (2022)

Real‐world clinical outcomes of olaparib therapy in Chinese patients with advanced serous ovarian cancer treated in Macau
por: Cao, Yabing, et al.
Publicado: (2019)

Olaparib induced senescence under P16 or P53 dependent manner in ovarian cancer
por: Wang, Zehua, et al.
Publicado: (2018)

Proguanil synergistically sensitizes ovarian cancer cells to olaparib by increasing DNA damage and inducing apoptosis
por: Wu, Yan, et al.
Publicado: (2022)

Inhibition of PKM2 Enhances Sensitivity of Olaparib to Ovarian Cancer Cells and Induces DNA Damage
por: Zhou, Sichun, et al.
Publicado: (2022)

Normalized LST Is an Efficient Biomarker for Homologous Recombination Deficiency and Olaparib Response in Ovarian Carcinoma
por: Christinat, Yann, et al.
Publicado: (2023)

Response of Estrogen-Receptor-Positive Metastatic Breast Cancer to Olaparib in Late-Line Therapy
por: Kumeta, Toko, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_4boajh05n18e3be8n9og1gni57